Editorial

HIV Preexposure Prophylaxis: Walking Ahead on Tightropes

Authors: Vineet Gupta, MD, Mohamed H. Yassin, MD, PhD

Abstract

The National HIV Surveillance Report estimated that by the end of 2008, there were approximately 1.2 million people living with human immunodeficiency virus (HIV) in the United States. Despite the decline in mortality from HIV, the incidence rate has remained steady, at approximately 50,000 cases per year.1 These startling incidence numbers speak of our helplessness in containing HIV transmission, fostering efforts toward developing robust prevention strategies.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Centers for Disease Control and Prevention. HIV surveillance—United States, 1981-2008. MMWR Morb Mortal Wkly Rep 2011; 60: 689–693.
 
2. Michael NL. Oral preexposure prophylaxis for HIV—another arrow in the quiver? N Engl J Med 2010; 363: 2663–2665.
 
3. Baeten J, et al. Antiretroviral pre-exposure prophylaxis for HIV-1 prevention among heterosexual African men and women: the Partners PrEP Study. Abstract MOAX0106. International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; Rome; July 17–20, 2011.
 
4. Thigpen M, Kebaabetswe PM, Smith DK, et al. Daily oral antiretroviral use for the prevention of HIV infection in heterosexually active young adults in Botswana: results from the TDF2 study. Abstract WELBC01. International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; Rome; July 17–20, 2011.
 
5. AVAC. Ongoing PrEP clinical trials. http://www.avac.org/ht/d/sp/i/3507/pid/3507. Accessed December 3, 2011.
 
6. UNAIDS. Report on HIV prevention research funding says new investment critical to capitalize on HIV prevention research breakthroughs. http://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2011/july/20110719rtwg. Published July 19, 2011. Accessed November 29, 2011.
 
7. Tripathi A, Ogbuanu U, Monger M, et al. Pre-exposure prophylaxis for HIV infection: healthcare providers’ knowledge, perception, and willingness to adopt future implementation in the southern US. South Med J 2012; 105: 199–206.
 
8. Naswa S, Marfatia YS. Pre-exposure prophylaxis of HIV. Indian J Sex Transm Dis 2011; 32: 1–8.
 
9. Kelesidis T, Landovitz RJ. Preexposure prophylaxis for HIV prevention. Curr HIV/AIDS Rep 2011; 8: 94–103.